Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), and connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes and Transactions
On August 4, 2014, several acquisitions of GSK Ordinary shares occurred at a price of 1,437.00 pence per share. These transactions resulted from the re-investment of dividends on shares held within an Individual Savings Account (ISA). The specific transactions were:
- Sir Andrew Witty: 101 shares
- Mr S M Bicknell: 110 shares
- Mr D S Redfern: 20 shares
- Mrs V A Whyte: 19 shares
- Lady C Witty (Connected Person): 8 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Confirm the share price of 1,437.00 pence per Ordinary share on August 4, 2014.
- Verify that the reported share acquisitions were solely due to dividend re-investment within ISAs.
- Review the full list of directors and PDMRs to ensure all required disclosures for the period were made.